Pharma Cold-Chain 3PL Quality Leader — Regional Healthcare Logistics

The mandate

The quality head departed after a regulator found temperature excursions closed without product-impact evidence, subcontracted lanes absent from qualification records and inconsistent escalation to marketing-authorisation holders. The 3PL stores and transports client-owned vaccines, biologics and specialty medicines under delegated quality agreements. Warehouse, transport and client teams now apply different release thresholds, while commercial managers cannot explain which deviations expose patients, licences or contractual liability.

The interim starts within two weeks for eight fixed months, spending four days each week in Kuala Lumpur and one at the Johor or Penang operations, with monthly Singapore client reviews. Recruitment for a permanent regional quality director begins only after the first effectiveness-testing round in month four. Four weeks of overlap are reserved for transfer, and no extension will be offered if the search or routine remediation slips.

Handover requires every critical observation to have accepted closure and effectiveness evidence, the qualified-lane register to include every actual subcontractor and border handoff, and excursion investigations to meet the agreed scientific and notification thresholds for twelve consecutive weeks. Monitoring systems must remain validated, two successor-led quality reviews must close actions on time, and affected client quality leaders must accept the renewed quality-agreement matrix.

The leader may quarantine inventory, suspend a lane or subcontractor, reject inadequate investigations, commission validation within the approved envelope and replace temporary quality resources. Product disposition remains with the authorised client quality person; permanent hires, facility capital above MYR 5 million, contract amendments and representations to regulators require board or client approval. Sales pressure cannot override these decision boundaries.

Commercial repricing, new warehouse construction, medicine manufacturing quality and redesign of clients' stability programmes are excluded. The mandate repairs the 3PL's custody, controlled storage, packing, transportation, subcontractor oversight and retained evidence. Pharmacovigilance, batch release and product formulation stay with clients, although their documented stability and notification requirements must govern the logistics response.

Why this seat is open

Regulatory findings revealed that the former leader's closure practice prioritised speed over scientific evidence. Local teams cannot independently judge controls they designed. The board needs temporary quality authority through proven remediation and succession.

What you will own

• Re-grade every observation and overdue action by product sensitivity, patient consequence, regulatory exposure, client obligation and likelihood of recurrence.
• Reopen weak excursion investigations and require defensible time-temperature integration, lane chronology, logger placement, stability evidence and authorised disposition rationale.
• Qualify warehouse zones, passive packaging, active containers, vehicles, international lanes, border handoffs and subcontractors against representative seasonal operating profiles.
• Reconcile logger downloads, thermal mapping, calibration status, alarm history and shipment milestones into an unbroken custody-and-condition evidence chain.
• Reset client quality agreements around disposition authority, notification clocks, deviation ownership, change control, subcontracting, record retention and audit access.
• Run an unannounced recall-and-excursion exercise across one international lane, measuring traceability, quarantine, communication and decision latency at every handoff.
• Transfer validation status, CAPA proof, qualified-lane decisions, client commitments and the inspection calendar through two successor-chaired quality forums.

Candidate qualifications

• Held regional quality-director authority in pharmaceutical cold-chain 3PL operations spanning controlled warehouses, transport partners and client quality agreements.
• Closed material GDP or comparable regulator observations with retained remediation and effectiveness evidence that survived later inspection or client audit.
• Assessed temperature-excursion impact using stability limits, packaging qualification, route chronology, sensor position and scientifically defensible uncertainty treatment.
• Qualified multi-party domestic and international lanes including subcontracted transport, airport or port dwell, customs clearance and final-mile handoffs.
• Exercised quarantine, provider suspension or lane-stop authority under commercial pressure and can evidence the patient-risk trigger and disposition outcome.
• Handed an inspection-ready quality system to permanent leadership with validated systems, current training, sustainable CAPA governance and accepted client obligations.

Non-negotiables

• Available within two weeks for the Malaysia and Singapore cadence.
• Independent of validation, packaging and monitoring vendors in scope.
• Will not release product or close CAPA without adequate evidence.
• Has director-level 3PL quality authority, not manufacturing QA alone.

1. 49 words maximum. State your earliest start and one cold-chain finding you closed with effectiveness proof.
2. 49 words maximum. Which evidence would make you reject an excursion investigation as scientifically inadequate?
3. 49 words maximum. Describe a subcontracted lane you suspended and the trigger used.